期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

CpGDNA佐剂研究进展 被引量：1

Research progress of immunoadjuvant CpG DNA
原文传递
导出
摘要 CpGDNA是含有非甲基化CpG基序的寡脱氧核苷酸，通过Toll样受体9（TLR9）激活树突状细胞（DC）和B细胞产生免疫应答。CpGDNA可以促进专职抗原呈递细胞有效地呈递抗原，从而增强疫苗的特异性免疫应答。目前使用CpGDNA佐剂的疫苗免疫后能维持长期免疫，具有明显的全身和黏膜免疫效果。临床前和临床试验表明，CpGDNA佐剂安全有效，能够提高传染病和肿瘤疫苗的效能，增强疫苗的免疫原性。 CpG DNA containing unmethylated CpG motifs directly activates human plasmacytoid dendritic cells and B cells to induce immune response via TLR9. CpG DNA can improve function of professional antigen-presenting cells and boost vaccine-specific immune responses. Immunization with vaccine and CpG DNA maintains persistent immunity, and has systemic and mucosal immune effects significantly. Preclinical and clinical trials demonstrate that CpG DNAs are safe and effective as vaccine adjuvants and can boost the efficacy and immunogenicity of vaccines targeting infectious diseases and cancer.
作者 孙燕(综述) 孟胜利(审校)
机构地区 中南民族大学武汉神经科学和神经工程研究所 武汉生物制品研究所有限责任公司狂犬病疫苗室
出处 《国际生物制品学杂志》 CAS 2012年第4期186-191,共6页 International Journal of Biologicals
关键词 佐剂 免疫 CPG DNA TOLL样受体 疫苗 Adjuvants,immunologic CpG DNA Toll-like receptor Vaccines
分类号 R512.62 [医药卫生—内科学]
  • 相关文献

参考文献54

  • 1Latz E, Schoenemeyer A, Visintin A, et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome [ J]. Nat Immunol, 2004, 5 (2) : 190-198.
  • 2He W, Yu Q, Zhou Z, et al. CpG oligonucleotides induce an immune response of odontoblasts through the TLR9, MyD88 and NF-kappaB pathways [J]. Biochem Biophys Res Commun, 2010, 399(2) :274-278.
  • 3江鑫,陈文魁.CpG DNA的免疫活性及应用前景[J].国际生物制品学杂志,2007,30(5):211-215. 被引量：1
  • 4Bode C, Zhao G, Steinhagen F, et al. CpG DNA as a vaccine adjuvant [J]. Expert Rev Vaccines, 2011, 10(4) :499-511.
  • 5Hartmann G, Krieg AM. Mechanism and function of a newly identified CpG DNA motif in human primary B cells [ J ]. J Immunol, 2000, 164(2) :944-953.
  • 6Mutwiri GK, Nichani AK, Babiuk S, et al. Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides [ J]. J Control Release, 2004, 97( 1 ) :1-17.
  • 7Verthelyi D, Ishii KJ, Gursel M, et al. Human peripheral blood ceils differentially recognize and respond to two distinct CPG motifs [J]. J Immunol, 2001,166(4) :2372-2377.
  • 8Guiducci C, Ott G, Chan JH, et al. Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation [ J ]. J Exp Med, 2006, 203 ( 8 ) : 1999-2008.
  • 9Samulowitz U, Weber M, Weeratna R, et al. A novel class of immune-stimulatory CpG ' oligodeoxynucleotides unifies high potency in type I interferon induction with preferred structural properties [J]. Oligonucleotides, 2010, 20(2):93-101.
  • 10Rynkiewicz D, Rathkopf M, Sim I, et al. Marked enhancement of the immune response to BioThrax ( Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers [ J ]. Vaccine, 2011, 29 ( 37 ) : 6313 -6320.

二级参考文献66

  • 1Davis HL. Use of CpG DNA for enhancing specific immune responses. Curr Top Microbiol Immunol,2000,247 : 171-181.
  • 2Moldoveanu Z, Love- Homan L, Huang WQ, et al. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine,1998,16(11/12) :1216-1224.
  • 3McCluskie MJ, Davis HL. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol,1998,161(9) :4463-4466.
  • 4Kovarik J, Bozzotti P, Love-Homan L, et al. CpG oligodeoxynucleotidescan circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming. J Immunol, 1999, 182 (3): 1811-1817.
  • 5Tighe H, Takabayashi K, Schwartz D, et al. Conjugation of protein to immunostimulatory DNA results in a rapid, long- lasting and potent induction of cell-mediated and humoral immunity. Eur J Immnuol,2000,30(7) :1939-1947.
  • 6Shirota H, Sano K, Hirasawa N, et al. B ceils capturing antigen conjugated with CpG oligodeoxynucleotides induce Thl cells by elaborating IL-12. J Immunol, 2002,169(2) : 787-794.
  • 7Baral RN, Saha A, Chatterjee SK, et al. Immunostimulatory CpG oligonucleotides enhance the immune response of anti-idiotypevaccine that mimics carcinoembryonic antigen. Cancer Immunol Immunother,2003,52(5) :317-327.
  • 8Warren TL, Weiner GJ. Synergism between cytosine-guanine oligodeoxynucleotides and monoclonal antibody in the treatment of lymphoma. Semin Oncol,2002,29(1 Suppl 2):93-97.
  • 9Klinman DM, Conover J, Coban C, et al. Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection. Infect Immun, 1999,67(11) : 5658-5663.
  • 10Zimmermann S, Egeter O, Hausmann S, et al. CpG oligodeoxynucleotides trigger protective and curative Thl responses in lethal murine leishmaniasis. J Immunol, 1998,160(8) :3627-3630.

共引文献3

同被引文献25

  • 1张馨玉,金华利,杨若耶,肖冲,朱开春,张富春,王宾.壳聚糖对口蹄疫DNA疫苗黏膜免疫的影响[J].中国农业大学学报,2005,10(5):21-25. 被引量：8
  • 2Ramon G. Sur l'augmentation anormale de l'antitoxine chez les chevaux producteurs de serum antidiphterique[J]. Bull Soc Centr Med Vet, 1925, 101:227-234.
  • 3Anja S, Samuele C, Laura S, et al. Adjuvanticity of the oil- in-water emulsion MF59 is independent ofNlrp3 inflammasome but requires the adaptor protein MyD88[J]. Proc Natl Acad Sci USA, 2011,108(27): 11169-11174.
  • 4Bal S M, Hortensius S, Ding Z, et al. Co-encapsulation of antigen and Toll-like receptor ligand in cationic liposomes af- fects the quality of the immune response in mice after intrader- mal vaccination[J]. Vaccine, 2011,29( 5 ): 1045-1052.
  • 5Yukihiko A, Yoshimine F, Kiyoto Y, et al. Activation of systemic and mucosal immune response following nasal admin- istration of liposomes[J]. Vaccine, 1994, 12( 13): 1241-1244.
  • 6Christensen D, Agger E M, Andreasen L V, et al. Liposome- based cationic adjuvant formulations (CAF): past, present and future[J]. J Liposome Res, 2009, 19: 2-11.
  • 7Cashion M P, Long T E. Biomimetic design and perfor- mance of polymerizable lipids[J]. Acc Chem Res,2009,42: 1016-1025.
  • 8Moon J J, Suh H, Bershteyn A, et al. Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent hum oral and cellular immune responses[J]. Nat Mater, 2011,10: 243- 251.
  • 9Cox E, Verdonck F, Vanrompay D, et al. Adjuvants modu- lating mucosal immune responses or directing systemic re- sponses towards the mueosa[J]. Vet Res, 2006, 37:511-539.
  • 10Abusugra I, Wolf G, Bolsker G, et al. ISCOM vaccine against Contagious bovine pieuro- pneumonia (CBPP)[J]. Vet lmmunol Immuopathol, 1997, 59( 12): 31-48.

引证文献1

二级引证文献16

国际生物制品学杂志
2012年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部